• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Zentek Provides Market Update on ZenGUARD(TM) Antimicrobial Surgical Masks

    10/17/24 8:00:00 AM ET
    $HSIC
    $ZTEK
    Medical Specialities
    Health Care
    Major Chemicals
    Industrials
    Get the next $HSIC alert in real time by email

    GUELPH, ON / ACCESSWIRE / October 17, 2024 / Zentek Ltd. ("Zentek" or the "Company") (NASDAQ:ZTEK)(TSXV:ZEN), an intellectual property development and commercialization company, is pleased to provide an update on recent commercialization activities for its ZenGUARD™Antimicrobial Surgical Masks.

    As previously announced on July 24, 2024, the Company embarked on a Canada-wide sampling program for dental professionals facilitated by Henry Schein Inc. ("Henry Schein") that saw ZenGUARD™ Antimicrobial Surgical Masks included in product shipments to Henry Schein customers across Canada. As a result of this program and the unique value proposition ZenGUARD™ Antimicrobial Surgical Masks bring to dental practitioners and their patients, the Company is now seeing increased demand from Henry Schein. Henry Schein (NASDAQ:HSIC) is the world's largest provider of health care solutions to office-based dental and medical practitioners with a presence in 33 countries.

    Zentek continues to explore opportunities in other markets including in the beauty space and in international healthcare and dental markets where demand for surgical masks is expected to be more stable long term.

    As previously announced on April 24, 2024, the Company applied to the Food and Drug Administration (FDA) for authorization to market and sell its ZenGUARD™ Surgical Masks in the United States. The FDA has requested additional information regarding ZenGUARD™ and the Company is currently evaluating the additional information requests.

    "In addition to better protection against infectious agents, ZenGUARD™ Antimicrobial Surgical Masks are also proven to eliminate 99.9% of bacteria, which can collect on the skin when wearing a surgical mask for extended periods and cause acne. We believe this unique value proposition will continue to drive increased demand in the dental market and is a very natural fit for the beauty industry as well. We look forward to continuing to build on the recent success generated in the Henry Schein sampling program and to expanding the platform globally." said Greg Fenton, Zentek CEO.

    About Zentek Ltd.

    Zentek is an ISO 13485:2016 certified intellectual property technology company focused on the research, development and commercialization of novel products seeking to give the Company's commercial partners a competitive advantage by making their products better, safer, and greener.

    Zentek's patented technology platform ZenGUARD™, is shown to have 99-per-cent antimicrobial activity and to significantly increase the viral filtration efficiency for surgical masks and aims to do the same for HVAC (heating, ventilation, and air conditioning) systems. Zentek's ZenGUARD™ production facility is in Guelph, Ontario.

    For further information on Zentek:

    [email protected]

    Ryan Shacklock
    Senior VP, Strategy & Business Development
    Email: [email protected]
    Phone: 306-270-9610

    To find out more about Zentek, please visit our website at www.Zentek.com. A copy of this news release and all material documents in respect of the Company may be obtained on Zentek's SEDAR+ profile at http://www.sedarplus.ca/.

    Forward-Looking Statements

    This news release contains forward-looking statements. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although Zentek believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Zentek disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.

    Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

    SOURCE: Zentek Ltd.



    View the original press release on accesswire.com

    Get the next $HSIC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Q&A

    New
    • What recent developments have been reported regarding Zentek's ZenGUARD™ Surgical Masks?

      Zentek Ltd. has reported an increase in demand for their ZenGUARD™ Antimicrobial Surgical Masks, particularly through a sampling program for dental professionals facilitated by Henry Schein Inc.

    • In addition to the dental market, what other markets is Zentek exploring for their surgical masks?

      Zentek is exploring opportunities in various markets, especially the beauty space and international healthcare and dental markets that show stable long-term demand for surgical masks.

    • What is the current status of Zentek's FDA application for ZenGUARD™ Surgical Masks?

      The FDA has requested additional information from Zentek regarding their application to market and sell ZenGUARD™ Surgical Masks in the United States, which is currently being evaluated by the Company.

    • What unique benefits do ZenGUARD™ Surgical Masks offer beyond protection from infectious agents?

      ZenGUARD™ Antimicrobial Surgical Masks are claimed to eliminate 99.9% of bacteria that can cause acne, making them not just protective but also beneficial for the skin.

    • What are Zentek's expectations for the future following the success of their recent sampling program?

      The Company is optimistic about its growth and global expansion plans, especially following the success from the Henry Schein sampling program.

    Recent Analyst Ratings for
    $HSIC
    $ZTEK

    CompanyDatePrice TargetRatingAnalyst
    Henry Schein Inc.
    $HSIC
    2/14/2025$80.00Equal Weight
    Wells Fargo
    Henry Schein Inc.
    $HSIC
    1/6/2025$69.00 → $84.00Underperform → Buy
    BofA Securities
    Henry Schein Inc.
    $HSIC
    12/4/2024$75.00Neutral
    Mizuho
    Henry Schein Inc.
    $HSIC
    7/22/2024$81.00 → $92.00Neutral → Outperform
    Robert W. Baird
    Henry Schein Inc.
    $HSIC
    2/26/2024$78.00Market Perform
    Leerink Partners
    Henry Schein Inc.
    $HSIC
    12/12/2023$71.00 → $82.00Neutral → Overweight
    JP Morgan
    Henry Schein Inc.
    $HSIC
    11/10/2023$70.00Hold → Buy
    Stifel
    Henry Schein Inc.
    $HSIC
    8/8/2022$80.00Sell → Neutral
    UBS
    More analyst ratings